Regeneron Pharmaceuticals (NASDAQ:REGN) Reaches New 12-Month Low – Time to Sell?

16 Nov 2024, 12:46 by Doug Wharley · The Cerbat Gem

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) hit a new 52-week low on Thursday . The company traded as low as $784.32 and last traded at $784.95, with a volume of 612102 shares. The stock had previously closed at $804.33.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on REGN. Piper Sandler lowered their target price on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. Citigroup started coverage on Regeneron Pharmaceuticals in a research note on Thursday. They set a “neutral” rating and a $895.00 target price on the stock. Guggenheim raised their price objective on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Cantor Fitzgerald restated a “neutral” rating and set a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. Finally, Leerink Partnrs lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,099.55.

Get Our Latest Research Report on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Price Performance

The company has a fifty day simple moving average of $985.21 and a 200 day simple moving average of $1,032.97. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The stock has a market capitalization of $83.17 billion, a price-to-earnings ratio of 18.73, a P/E/G ratio of 3.04 and a beta of 0.15.

Insider Transactions at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. This trade represents a 27.07 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 7.48% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Quent Capital LLC increased its position in Regeneron Pharmaceuticals by 5.1% in the 1st quarter. Quent Capital LLC now owns 390 shares of the biopharmaceutical company’s stock valued at $375,000 after buying an additional 19 shares in the last quarter. Dorsey & Whitney Trust CO LLC increased its position in Regeneron Pharmaceuticals by 26.8% in the 1st quarter. Dorsey & Whitney Trust CO LLC now owns 587 shares of the biopharmaceutical company’s stock valued at $565,000 after buying an additional 124 shares in the last quarter. Acadian Asset Management LLC increased its position in Regeneron Pharmaceuticals by 37.2% in the 1st quarter. Acadian Asset Management LLC now owns 62,141 shares of the biopharmaceutical company’s stock valued at $59,794,000 after buying an additional 16,856 shares in the last quarter. Cercano Management LLC acquired a new position in Regeneron Pharmaceuticals during the 1st quarter valued at about $36,953,000. Finally, Edgestream Partners L.P. purchased a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth approximately $7,352,000. 83.31% of the stock is owned by institutional investors.

About Regeneron Pharmaceuticals

(Get Free Report)